EU-RAS brings together researchers, clinicians and industry partners to further our understanding of RAS biology and translate advances into new therapeutic strategies and better outcomes for patients
Progress in understanding RAS-driven cancers relies on collaboration across disciplines, institutions and geographic boundaries. Molecular biologists, clinicians, computational scientists and translational researchers each contribute unique perspectives to a complex problem.
The European RAS Association aims to support knowledge exchange, encourage interdisciplinary discussion and strengthen connections within the cancer research community, with RAS signaling as a shared focal point.
In sum, EU-RAS aims to provide a European platform where academic investigators, clinical researchers, biotechnology and pharmaceutical companies can identify shared scientific challenges, develop collaborative projects, and accelerate the translation of emerging RAS-targeted strategies.
